Physician profile
Lawrence H Matt
NPI 1326166521
$2,019.99
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $457 · 2021: $657 · 2022: $262 · 2023: $167 · 2024: $39.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $206.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $329.29 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $224.82 | 2019-2021 | |
| Almirall LLC | $183.75 | 2019-2021 | |
| Janssen Biotech, INC. | $177.52 | 2020-2024 | Tremfya |
| Galderma Laboratories, L.P. | $167.11 | 2019-2021 | |
| Merz North America, INC. | $155.67 | 2019-2023 | Xeomin |
| Lilly USA, LLC | $132.36 | 2021-2022 | |
| Allergan, INC. | $109.56 | 2019-2021 | |
| Leo Pharma INC. | $108.93 | 2019-2022 | |
| Ucb, INC. | $81.11 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $77.95 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $59.21 | 2020 | |
| Incyte Corporation | $49.32 | 2022-2023 | Opzelura |
| Dermira, INC. | $34.75 | 2021 | |
| Amgen INC. | $31.98 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $27.85 | 2019 | |
| Vyne Pharmaceuticals INC. | $26.84 | 2020 | |
| Genzyme Corporation | $22.40 | 2022 | |
| Dermavant Sciences, INC. | $19.57 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Matt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.